<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931097</url>
  </required_header>
  <id_info>
    <org_study_id>C15-46</org_study_id>
    <secondary_id>2016-A00792-49</secondary_id>
    <nct_id>NCT02931097</nct_id>
  </id_info>
  <brief_title>DBS of the MLR for Gait and Balance Disorders in PD Patients</brief_title>
  <acronym>GAITPARK</acronym>
  <official_title>Effects of Deep Brain Stimulation of the Mesencephalic Locomotor Region on Gait and Balance Disorders in Parkinson's Disease Patients : a Randomized, Double-blind, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gait and balance disorders represent the main motor disability in advanced Parkinson's&#xD;
      disease. These symptoms are less or unresponsive to levodopa treatment and are considered to&#xD;
      be a contraindication for deep brain stimulation of the subthalamic nucleus. Falls and&#xD;
      freezing of gait are responsible for high morbidity (fractures, residential health care) and&#xD;
      increased significantly mortality. The pathophysiology of gait and balance disorders is still&#xD;
      poorly understood, but recent data obtained in animals and humans suggest that a degeneration&#xD;
      of cholinergic neurons of the pedunculopontine nucleus (PPN), within the mesencephalic&#xD;
      locomotor region, could play a crucial role. In line with this hypothesis, low-frequency&#xD;
      stimulation of the pedunculopontine area, thought to increase the activity of the remaining&#xD;
      cholinergic PPN neurons, has been proposed to alleviate gait and balance disorders in&#xD;
      advanced PD patients. Here, the efficacy of deep brain stimulation of the mesencephalic&#xD;
      locomotor region will be tested in 12 PD patients in a randomized, double-blind, cross-over,&#xD;
      controlled study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the anticipatory postural adjustments between each deep brain stimulation condition</measure>
    <time_frame>3, 5, 7 months after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Pedunculopontine stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep brain stimulation of the pedunculopontine area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pontomesencephalic stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep brain stimulation of the pontomesencephalic area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No deep brain stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep brain stimulation</intervention_name>
    <description>Stimulating deep brain electrodes and pulse generator</description>
    <arm_group_label>Pedunculopontine stimulation</arm_group_label>
    <arm_group_label>Pontomesencephalic stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham stimulation</intervention_name>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age below 71 years&#xD;
&#xD;
          -  severe form of Parkinson's Disease with disease duration &gt; 5 years&#xD;
&#xD;
          -  presence of gait and/or balance disorders unresponsive to levodopa treatment,&#xD;
&#xD;
          -  &gt; 40% decrease in others motor symptoms with levodopa treatment&#xD;
&#xD;
          -  health insurance&#xD;
&#xD;
          -  give signed informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  dementia (Mattis Dementia Rating Scale &lt; 129, MDRS),&#xD;
&#xD;
          -  ongoing psychiatric disturbances,&#xD;
&#xD;
          -  surgical contraindications&#xD;
&#xD;
          -  significant brain lesions detected on MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Laure Welter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriellle Derocle</last_name>
    <email>gabrielle.derocle@inserm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique-Institut du Cerveau et de la Moelle Epiniere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Coudoin, Nurse</last_name>
      <phone>+33142165772</phone>
      <email>sylvie.coudoin@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Laure Welter, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine Karachi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Deep brain stimulation</keyword>
  <keyword>Mesencephalic locomotor region</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

